6th TPD and Induced Proximity Summit Europe

Memo

The 6th TPD and Induced Proximity Summit Europe is the only European forum dedicated exclusively to proximity-based drug discovery. From PROTACs and molecular glues to stabilizers and extracellular degraders, this summit showcases the full spectrum of therapeutic innovation across oncology, neurodegeneration, immunology, and rare diseases. Held in London in March 2026, the event brings together more than 80 CxOs, directors, senior scientists and investors to accelerate proximity therapeutics from discovery to clinic. Europe is experiencing a surge in strategic investment and innovation, including Sanofi’s acquisition of Blueprint Medicines for £7.2 billion and Merck’s £2.7 billion purchase of SpringWorks Therapeutics. As the region pivots toward non-oncology indications and novel mechanisms, drug developers face challenges in rational design, oral bioavailability, PK and PD modelling, and clinical translation. This summit addresses those challenges with insights from leading companies such as GSK, Abbvie, Amphista, Autotac Bio, PhoreMost, Laigo Bio, and Foghorn Therapeutics. Attendees will gain access to first-in-human data, biology-first strategies, and novel degradation platforms that are redefining the druggable proteome. Whether you are advancing early discovery or preparing clinical candidates, this is your essential opportunity to connect with Europe's most innovative biopharma teams and stay ahead in the evolving induced proximity landscape. URLs:Tickets: https://go.evvnt.com/3355369-2?pid=5569 Brochure: https://go.evvnt.com/3355369-3?pid=5569  Date and Time: Tue, 10 Mar 2026 08:00 - Thu, 12 Mar 2026 18:00 Venue details: Millennium Hotel and Conference Centre Gloucester London, 4-18 Harrington Gardens, London, England, SW7 4LH, United Kingdom Prices:Drug Developer Pricing - 3 Day Pass (Conference + Workshop Day): GBP 3797.00,Drug Developer Pricing - 2 Day Pass (Conference Only): GBP 2699.00,Academic Pricing - 3 Day Pass (Conference + Workshop Day): GBP 3197.00,Academic Pricing - 2 Day Pass (Conference Only): GBP 2299.00,Service Provider Pricing - 3 Day Pass (Conference + Workshop Day): GBP 4497.00,Service Provider Pricing - 2 Day Pass (Conference Only): GBP 3199.00   Speakers: Georg Winter, Life Science Director, AITHYRA Institute for Biomedical AI, Victor Guallar, ICREA Professor and Group Leader, Barcelona Supercomputing Group, Zoran Rankovic, Director and Professor - Chemical Biology and Protein Degradation, Center for Protein Degradation, Institute of Cancer Research, Radoslaw Nowak, Professor of Immune Engineering and Drug Discovery, The University of Bonn, Alessio Ciulli, Founder, Director and Professor - Chemical, Structural Biology and Centre for Targeted Protein Degradation, University of Dundee, Laura Gasparini, Scientific Director and Tau Pathobiology Area Leader, Abbvie, Christopher Woelk, External Innovation Partner, Astellas Pharma, Carlos Martinez, Fleites Scientific Leader, Molecular Modalities Discovery, GlaxoSmithKline, Christin Rakers, Principal Scientist Computational Chemistry, Merck, Björn Niebel, Senior Principal Scientist, Sanofi, Large Molecule Research, Damian Crowther, Entrepreneur In Residence, Cambridge Innovation Capital and SV Health Investors DDF, Mary Canning, Partner, Epidarex Capital, Luka Nicin, Venture Capitalist, Pace Ventures, Tiziana Rosetti, Principal, Sofinnova Partners, Christian Ottmann, Associate Professor, Ambagon Therapeutics, Louise Modis, Chief Scientific Officer, Amphista, Changhoon Ji, Chief Technology Officer, Autotac Bio, George Crane, Co-Founder and Chief Executive Officer, Bindbridge, Simon Glerup, Chief Scientific Officer, Draupnir Bio, Shyra Gardai, Chief Scientific Officer, EpiBiologics, Jamie Im, Director, Medicinal Chemistry, Foghorn Therapeutics, Ian Churcher, CEO and Founder, Janus Drug Discovery Consulting, Maureen Galmes-Spit, Vice President - Research, Laigo Bio, Christian Dillon, Chief Scientific Officer, PhoreMost, Kirill Pevzner, Chief Technology Officer and Co-Founder, Protai Bio, Chris Tame, Founder and Chief Executive Officer, Ternary Therapeutics, Martin Stahl, Chief Scientific Officer, Zenith Therapeutics